US Stock Market Move | NIKE, Inc. Class B (NKE.US) rose in pre-market trading as the CEO spent $1 million to increase his stock holdings.
After Nike's CEO invested $1 million in stocks, Nike's share price rose.
On the last trading day of 2025, as of the time of drafting, the stock price of NIKE, Inc. Class B (NKE.US) rose by 2.93% to $62.98 before the market opened on Wednesday; former CEO Elliott Hill had increased his stake in the company. NIKE, Inc. Class B disclosed in a filing to the U.S. Securities and Exchange Commission (SEC) that Hill purchased 16,388 shares at a price of $61.10 per share on December 29th. The value of Hill's recent purchase of NIKE, Inc. Class B shares slightly exceeded $1 million, and he currently holds 241,587 shares.
Hill returned to work for NIKE, Inc. Class B at the end of 2024. Previously, he retired from NIKE, Inc. Class B in 2020, ending a 32-year career with the company. He is widely regarded as a "lifelong employee" of NIKE, Inc. Class B, with deep industry knowledge and a consumer-centric philosophy. Analysts believe that his return to NIKE, Inc. Class B could be a key moment in turning around the company's performance.
The 52-week stock price range for NIKE, Inc. Class B is $52.28 to $82.44. The stock price has not reached three digits since March 2024.
Related Articles

New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).






